ES8404858A1 - Un procedimiento para la purificacion de un anticuerpo. - Google Patents

Un procedimiento para la purificacion de un anticuerpo.

Info

Publication number
ES8404858A1
ES8404858A1 ES521371A ES521371A ES8404858A1 ES 8404858 A1 ES8404858 A1 ES 8404858A1 ES 521371 A ES521371 A ES 521371A ES 521371 A ES521371 A ES 521371A ES 8404858 A1 ES8404858 A1 ES 8404858A1
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
affinity purification
antibodies
antigens
environment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES521371A
Other languages
English (en)
Other versions
ES521371A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES521371A0 publication Critical patent/ES521371A0/es
Publication of ES8404858A1 publication Critical patent/ES8404858A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

METODO DE PURIFICACION DE ANTICUERPOS CON GRAN AFINIDAD POR UN ANTIGENO EN UN PRIMER MEDIO AMBIENTE Y BAJA AFINIDAD POR EL MISMO EN UN SEGUNDO MEDIO AMBIENTE.CONSISTE EN INMOVILIZAR EL ANTIGENO SOBRE UN SOPORTE SOLIDO; FIJAR EL ANTICUERPO AL ANTIGENO EN EL PRIMER MEDIO AMBIENTE QUE TIENE UN PH ENTRE 4 Y 10,5, SEPARAR LAS IMPUREZAS NO FIJADAS DESDE EL ANTICUERPO; Y ELUIR EL ANTICUERPO PURO DESDE EL ANTIGENO MEDIANTE UN ELUYENTE, CONSTITUIDO POR UN SEGUNDO MEDIO AMBIENTE QUE ES UNA DISOLUCION QUE CONTIENE UN AGENTE CAOTROPICO A OTRO PH ENTRE 4 Y 10,5.ESTOS COMPUESTOSTIENEN APLICACIONES FARMACOLOGICAS POR SUS PROPIEDADES INMUNOQUIMICAS Y/O BIOLOGICAS.
ES521371A 1982-04-12 1983-04-11 Un procedimiento para la purificacion de un anticuerpo. Expired ES8404858A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778182A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES521371A0 ES521371A0 (es) 1984-05-16
ES8404858A1 true ES8404858A1 (es) 1984-05-16

Family

ID=23448565

Family Applications (3)

Application Number Title Priority Date Filing Date
ES521371A Expired ES8404858A1 (es) 1982-04-12 1983-04-11 Un procedimiento para la purificacion de un anticuerpo.
ES528001A Expired ES8706964A1 (es) 1982-04-12 1983-12-13 Un procedimiento para fraccionar anticuerpos de suero.
ES528000A Granted ES528000A0 (es) 1982-04-12 1983-12-13 Un procedimiento para la purificacion de un antigeno.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES528001A Expired ES8706964A1 (es) 1982-04-12 1983-12-13 Un procedimiento para fraccionar anticuerpos de suero.
ES528000A Granted ES528000A0 (es) 1982-04-12 1983-12-13 Un procedimiento para la purificacion de un antigeno.

Country Status (11)

Country Link
EP (1) EP0105359A4 (es)
AT (1) AT393386B (es)
AU (1) AU622099B2 (es)
CA (1) CA1209907A (es)
CH (1) CH672028A5 (es)
DK (1) DK192191D0 (es)
ES (3) ES8404858A1 (es)
FI (1) FI88403C (es)
GB (1) GB2128630B (es)
IT (1) IT1219779B (es)
WO (1) WO1983003678A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) * 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
GB8331071D0 (en) * 1983-11-22 1983-12-29 Karayiannis P Assay for dna/rna
US4666865A (en) * 1984-01-13 1987-05-19 Centocor, Inc. Immunoassay for biologically active human interferon-gamma employing unique monoclonal antibodies
US4789631A (en) * 1984-02-17 1988-12-06 Synbiotics Corporation Immunoassay for anti-dirofilaria immitis antibody
GB8426468D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
AU5259786A (en) * 1985-01-30 1986-08-07 United States Of America, The Monoclonal antibodies against chlamydial genes specific lipopolysaccharide
US4818687A (en) * 1985-02-28 1989-04-04 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
US4859611A (en) * 1985-02-28 1989-08-22 Massachusetts Institute Of Technology Affinity column and process for detection of low molecular weight toxic substances
IL75828A (en) * 1985-07-17 1991-06-10 Univ Ramot Immobilization by biologically active proteins
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5175255A (en) * 1987-03-23 1992-12-29 Amgen Inc. Methods for purification of platelet-derived growth factor
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
SE468653B (sv) * 1987-03-06 1993-02-22 Perstorp Biolytica Adsorbent foer isokratisk affinitetskromatografi
JPS6463599A (en) * 1987-05-01 1989-03-09 Xoma Corp Purification of immunoglobulin by selective anti-idiotype bond
JPH03500682A (ja) * 1987-07-14 1991-02-14 ザ　ビクトリア　ユニヴアーシテイ　オブ　マンチエスター 診断方法
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JP2001502895A (ja) * 1996-09-20 2001-03-06 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
ES2563483T3 (es) * 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
KR20230044338A (ko) 2014-12-19 2023-04-03 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
ATE14269T1 (de) * 1981-02-26 1985-08-15 Unilever Nv Verfahren und vorrichtung zur rueckgewinnung von immunoglobulinen.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Also Published As

Publication number Publication date
CA1209907A (en) 1986-08-19
ES8506902A1 (es) 1985-08-01
ES528000A0 (es) 1985-08-01
ES521371A0 (es) 1984-05-16
AT393386B (de) 1991-10-10
AU7256987A (en) 1987-09-03
FI88403C (fi) 1993-05-10
FI88403B (fi) 1993-01-29
EP0105359A1 (en) 1984-04-18
FI834530A0 (fi) 1983-12-09
ATA901983A (de) 1991-03-15
ES8706964A1 (es) 1987-07-01
GB2128630A (en) 1984-05-02
DK192191A (da) 1991-11-26
IT1219779B (it) 1990-05-24
EP0105359A4 (en) 1984-08-20
DK192191D0 (da) 1991-11-26
GB8332644D0 (en) 1984-01-11
WO1983003678A1 (en) 1983-10-27
AU622099B2 (en) 1992-04-02
IT8320550A0 (it) 1983-04-12
FI834530A (fi) 1983-12-09
CH672028A5 (es) 1989-10-13
ES528001A0 (es) 1987-07-01
GB2128630B (en) 1986-08-28

Similar Documents

Publication Publication Date Title
ES8706964A1 (es) Un procedimiento para fraccionar anticuerpos de suero.
ES8206856A1 (es) Mejoras en un metodo y su correspondiente equipo de ensayo para determinar antigenos por medio de una reaccion inmuno- quimica
AU1964883A (en) Monoclonal antibody immunoassay
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
EP0098162A3 (en) Monoclonal antibodies specific to carcinoembryonic antigen
DK0432249T3 (da) Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf
MY101457A (en) Toxins and antibodies of c.difficile.
AU564575B2 (en) Polyvalent endotoxin specific antibodies
AU567681B2 (en) Immunoassay involving monoclonal igm antibody
MY100328A (en) Toxins and antibodies of c.difficile
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
CA2054689A1 (en) An immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen
ES8401261A1 (es) Soportes de materia plastica revestidos de un segundo anticuerpo.
ES8704351A1 (es) Un procedimiento para preparar un anticuerpo monocional anti-urocinasa.
EP0186371A3 (en) Monoclonal antibodies specific to antigens of hepatitis b virus
AU2900184A (en) Membrane antigens generated from pooled cells and monoclonal antibodies
EP0089771A3 (en) Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan
AU1550783A (en) Method of affinity purification employing monoclonal antibodies
DE3174878D1 (en) Immunoassay utilizing monoclonal high affinity igm antibodies
CA2178504A1 (en) Immunoassays for prostate specific antigen

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401